Aspargo Laboratories
Aspargo Labs, a biopharmaceutical firm, develops oral sprays for erectile dysfunction, approved in 17 countries.
Founded
2019Aspargo Labs, a biopharmaceutical firm, develops oral sprays for erectile dysfunction, approved in 17 countries.
Aspargo Laboratories, founded with a mission to develop innovative patient-focused biopharmaceutical solutions, specializes in oral spray formulations for treating erectile dysfunction. Their flagship product is an oral suspension spray of sildenafil citrate, the active ingredient in Viagra, designed for convenient administration and flexible dosing. This product aims to improve accessibility for patients with dysphagia, offering a significant advancement in the erectile dysfunction treatment market.
Notably, Aspargo Labs' oral spray has gained approval in 17 countries, showcasing its international reach and impact. The company leverages proprietary trade secrets and expertise to maintain a competitive edge in the biopharmaceutical industry. By focusing on innovative delivery methods and patient-centric solutions, Aspargo Laboratories has made significant strides in addressing unmet medical needs, thereby enhancing the quality of life for many patients globally.
Companies similar to Aspargo Laboratories include ARS Pharmaceuticals, NovaDel Pharma, Concours Pharmaceuticals and Assertio Holdings.
Aspargo Laboratories was founded in 2019.
Aspargo Laboratories' headquarters is located in Englewood, NJ, US.
Aspargo Laboratories' most recent funding round was for $60M (USD) in March 2022.
As of Mar 28, 2022, Aspargo Laboratories has disclosed funding of $67.9M (USD). Undisclosed round amounts are excluded.
Aspargo Laboratories has 9 employees as of Feb 5, 2024.
Assertio Holdings
